A Warm Welcome from Prof. Francesco Giorgino | EASD 2025
&feature=youtu.be
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial
Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.
ASCO China Voice | Professor Zhiming Li: First Phase I Clinical Study Results of a CCR8-Targeting Antibody Drug for Relapsed/Refractory Cutaneous T-Cell Lymphoma Announced
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous malignant lymphoma originating from the skin and evolving from T-cells. It accounts for approximately 4% of non-Hodgkin lymphoma cases, classifying it as a…
test
document.getElementById("video").style.height=document.getElementById("video").scr
Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…
“50 Years of Hematopoietic Stem Cell Transplantation”
We were honored to hear from Professor Xiaojun Huang of Peking University People’s Hospital and the Peking University Institute of Hematology, who shared a comprehensive reflection on the global evolution of hematopoietic stem cell transplantation (HSCT).
From Dr. Edward Donnall Thomas' foundational work to the creation of the Beijing Protocol, Professor Huang spotlighted how China’s innovations—including non–T-cell-depleted haploidentical transplantation—are transforming clinical practice worldwide.
Can We Prevent CAR T-Associated Neurotoxicity Without Compromising Efficacy?
At EBMT25, Dr. Janaki Manoja Vinnakota presented compelling data on the role of microglial TAK1 activation in the development of CAR T cell therapy-associated neurotoxicity (ICANS). In her presentation titled…
EAU25 Interview Highlights | Prof. Samson Chan & Prof. Junlong Zhuang on PARPi in mHSPC
At the 2025 EAU Congress, Prof. Junlong Zhuang (Nanjing Drum Tower Hospital) and Prof. Samson Chan (Department of Surgery, Tuen Mun Hospital, Hong Kong) sat down with Urology Frontier to discuss new insights from the Phase II PROact study.
The study evaluated a triple combination of olaparib + abiraterone + prednisone in metastatic hormone-sensitive prostate cancer (mHSPC). According to the professors, early data show promising efficacy and manageable safety—suggesting PARP inhibitors may soon have a role beyond mCRPC in the prostate cancer treatment landscape.
A potential step forward in precision therapy for prostate cancer.
Watch the full interview now to hear their perspectives on the evolving role of PARPi in mHSPC.
New Hope for Drug-Resistant TB: MBLA Outperforms Xpert in Predicting Treatment Success
A new study published in the Journal of Infection reveals that the Molecular Bacterial Load Assay (MBLA) provides a faster and more accurate way to monitor treatment response in patients with pre-XDR/XDR-TB, compared to the widely used GeneXpert Ultra MTB/RIF test.
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer Editor's Note: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to…